Cancer Drugs Fund
Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund
July 7, 2016Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif
The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …
Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance
May 26, 2016Research and Development, Sales and Marketing Cancer Drugs Fund, Eli Lilly, NICE, lung cancer
The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat …
A win for Sanofi on Jevtana after NICE reverses guidance
April 22, 2016Medical Communications, Sales and Marketing Cancer Drugs Fund, Jevtana, NICE, Sanofi, recommendation, reversal
Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …
Janssen slams NICE decision on Imbruvica
March 2, 2016Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica
Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …
Eisai slams new Cancer Drugs Fund for delaying patient access
February 26, 2016Research and Development, Sales and Marketing Cancer Drugs Fund, Eisai, Lenvima
Eisai has aimed strong criticism at NHS England for its approval of reforms to the Cancer Drugs Fund, calling the …
INTERVIEW: AstraZeneca on the Cancer Drugs Fund reforms
February 26, 2016Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund
Greg Rossi, head of the Oncology Business Unit, AstraZeneca UK and Ireland, and the company’s market access team, spoke to …
NHS England approves Cancer Drugs Fund proposals
February 26, 2016Medical Communications, Research and Development ABPI, Cancer Drugs Fund, NHS England
NHS England has approved proposed reforms of the Cancer Drugs Fund, following the end of the 12-week consultation period earlier …
Novartis says CDF proposals place “unreasonable” risk on pharma
February 10, 2016Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Novartis
Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …
Parliamentary committee says CDF must make better use of taxpayer money
February 5, 2016Medical Communications Cancer Drugs Fund, Public Accounts Committee
The Cancer Drugs Fund, set up to improve patients’ access to cancer drugs, has not been managed effectively, a UK …
A brighter future for the Cancer Drugs Fund?
January 14, 2016Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Prostate Cancer UK
In November 2015, NICE and NHS England announced proposed changes to the operation of the Cancer Drugs Fund. This is …
NHS England and NICE announce plans for new Cancer Drugs Fund
November 19, 2015Medical Communications, Research and Development Cancer Drugs Fund, NHS England, NICE
A 12-week consultation on draft proposals for a revamped Cancer Drugs Fund (CDF) has been launched by NHS England and NICE, …
NICE rejects Roche’s Kadcyla for NHS; price still too high
November 17, 2015Manufacturing and Production, Sales and Marketing Cancer Drugs Fund, Kadcyla, NHS England, NICE, Roche
NICE has published final draft guidance on Roche’s Kadcyla as a breast cancer treatment, deciding that the drug’s price remains …
NHS England reinstates treatments to Cancer Drugs Fund
November 4, 2015Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NHS England
Five treatments in seven indications have been reinstated to Cancer Drugs Fund, as a result of negotiations between pharma companies …
Roche under pressure to drop price of Kadcyla
October 27, 2015Manufacturing and Production Cancer Drugs Fund, Kadcyla, Roche, breast cancer
The UK’s largest breast cancer charity has called for drug manufacturer Roche to drop the price of Kadcyla before it …
ABPI responds to UK medicines cost controversy
September 25, 2015Medical Communications, Sales and Marketing ABPI, Cancer Drugs Fund, NHS
Alison Clough, acting CEO of the Association of the British Pharmaceutical Industry (ABPI), has responded to recent reports in the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
